IP Verse

Methods And Products For Evaluating An Immune Response To A Therapeutic Agent - EP2645106

The patent EP2645106 was granted to Biogen Idec MA on Oct 2, 2024. The application was originally filed on Apr 4, 2006 under application number EP13158951A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2645106

BIOGEN IDEC MA
Application Number
EP13158951A
Filing Date
Apr 4, 2006
Status
Patent Maintained As Amended
Aug 30, 2024
Grant Date
Oct 2, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PHARMACEUTICAL WORKS POLPHARMAMar 9, 2018WICHMANNADMISSIBLE

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0239400
DESCRIPTIONUS2003070185
DESCRIPTIONUS2003232333
DESCRIPTIONUS3817837
DESCRIPTIONUS3850752
DESCRIPTIONUS3939350
DESCRIPTIONUS3996345
DESCRIPTIONUS4275149
DESCRIPTIONUS4277437
DESCRIPTIONUS4366241
DESCRIPTIONUS4399216
DESCRIPTIONUS4472509
DESCRIPTIONUS4634665
DESCRIPTIONUS4938948
DESCRIPTIONUS5179017
DESCRIPTIONUS5530101
DESCRIPTIONUS5585089
DESCRIPTIONUS5648260
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5789650
DESCRIPTIONUS5798230
DESCRIPTIONUS5840299
DESCRIPTIONUS5849992
DESCRIPTIONUS5888507
DESCRIPTIONUS6407213
DESCRIPTIONUS6602503
DESCRIPTIONWO9007861
DESCRIPTIONWO9634096
OPPOSITIONEP66840405P
OPPOSITIONWO2006107962
SEARCHWO03016909

Non-Patent Literature (NPL) Citations (43) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, pages 86 - 95-
DESCRIPTION- BURTON; WOOF, ADV. IMMUNOL., (1992), vol. 51, pages 1 - 84-
DESCRIPTION- Current Protocols in Molecular Biology, JOHN WILEY & SONS, (1989), pages 6.3.1 - 6.3.6-
DESCRIPTION- F.M. AUSUBEL, ET AL.,, Current Protocols in Molecular Biology, JOHN WILEY & SONS, INC.-
DESCRIPTION- GREEN ET AL., NATURE GENETICS, (1994), vol. 7, pages 13 - 21-
DESCRIPTION- HEMLER ET AL., J. BIOL. CHEM., (1987), vol. 2, pages 11478 - 11485-
DESCRIPTION- HOOGENBOOM ET AL., IMMUNOL TODAY, (2000), vol. 2, pages 371 - 8-
DESCRIPTION- HOOGENBOOM ET AL., IMMUNOTECHNOLOGY, (1998), vol. 4, pages 1 - 20-
DESCRIPTION- HUANG; STOLLAR, J. IMMUNOL. METHODS, (1991), vol. 141, pages 227 - 236-
DESCRIPTION- ISSEKUTZ; WYKRETOWICZ, J. IMMUNOL., (1991), vol. 147, page 109-
DESCRIPTION- JEFFERIS ET AL., IMMUNOL. REV., (1998), vol. 163, pages 59 - 76-
DESCRIPTION- KAUFMAN; SHARP, MOL. BIOL., (1982), vol. 159, pages 601 - 621-
DESCRIPTION- PERSSON ET AL., PROC. NAT. ACAD. SCI. USA, (1991), vol. 88, pages 2432 - 2436-
DESCRIPTION- POWERS ET AL., J IMMUNOL METHODS., (2001), vol. 251, pages 123 - 35-
DESCRIPTION- PULIDO ET AL., J. BIOL. CHEM., (1991), vol. 266, no. 16, pages 10241 - 10245-
DESCRIPTION- QUEEN ET AL., PROC NATL ACAD SCI U S A. DEC, (1989), vol. 86, no. 24, pages 10029 - 33-
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327-
DESCRIPTION- SANCHEZ-MADRID ET AL., EUR. J. IMMUNOL., (1986), vol. 16, pages 1343 - 1349-
DESCRIPTION- SHEREMATA ET AL., NEUROLOGY, (1999), vol. 52, page 1072-
DESCRIPTION- SHEREMATA ET AL., NEUROLOGY, (1999), vol. 52, pages 1072 - 1074-
DESCRIPTION- TEMPEST ET AL., BIOTECHNOLOGY, (1991), vol. 9, pages 266 - 271-
DESCRIPTION- URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, pages 4216 - 4220-
DESCRIPTION- VAUGHAN ET AL., NAT BIOTECHNOL. MAR, (1996), vol. 14, no. 3, pages 309 - 14-
DESCRIPTION- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536-
OPPOSITION- "< 1106> Immunogenicity Assays - Design and Validation of Immunoassays to detect Anti- Drug Antibodies", Pharmacopeia, (20130000), pages 5732 - 5744, XP055476882-
OPPOSITION- "Antibody product catalogue of Maine Biotechnology Services Inc.", Maine Biotechnology Services, (20150000), XP055476851-
OPPOSITION- CALABRESI PA et al., "SAFETY AND TOLERABILITY OF NATALIZUMAB: RESULTS FROM THE SENTINEL TRIAL", Neurology, (20050000), vol. 64, no. 6, page A277, XP009073089-
OPPOSITION- Captures of the products offered by Maine Biotechnology-
OPPOSITION- ROSKOS LK et al., "HUMAN ANTIGLOBULIN RESPONSES", Measuring Immunity, (20050000), pages 172 - 186, XP008058931-
OPPOSITION- ROSSMAN, H.S., "Neutralizing Antibodies to Multiple Sclerosis Treatments", Supplement to Journal of Managed Care Pharmacy, (20040600), vol. 10, no. 3, pages S12 - S18, XP055476759-
OPPOSITION- "Safety and Efficacy of Natallzumab in the Treatment of Multiple Sclerosis", ClinicalTrials.gov, (20010000), page C-1801 and C-1802, XP055476821-
OPPOSITION- SHEREMATA et al., "A Safety and Pharmacokinetic Study of Intravenous Natalizumab in Patients with MS", Neurology, (19990000), vol. 52, no. 5, pages 1072 - 1074, XP002997442-
OPPOSITION- SUBRAMANYAM M, "Case Study: Immunogenicity of N atalizumab", Biotechnology: Pharmaceutical Aspects, (20080000), pages 173 - 187, XP055476763-
OPPOSITION- William Ying Khee Hwang et al., "Immunogenicity of engineered antibodies", Methods, (20050100), vol. 36, no. 1, pages 3 - 10, XP027216558-
OPPOSITION- GIOVANNONI et al., "Sa.32. The Immunogenicity of Natalizumab in Patients with Multiple Sclerosis", Clinical Immunology, (20060000), vol. 119, page S116, XP005438506
OPPOSITION- MIRE-SLUIS et al., "Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products", Journal of Immunological Methods, (20040000), vol. 289, pages 1 - 16, XP004520874
OPPOSITION- CALABRESI et al., "The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL", Neurology, (20070000), vol. 69, pages 1391 - 1403, XP002694856
SEARCH- CALABRESI PETER A ET AL, "Safety and tolerability of natalizumab: Results from the SENTINEL trial", NEUROLOGY, & 57TH ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; MIAMI BEACH, FL, USA; APRIL 09 -19, 2005, (200503), vol. 64, no. 6, Suppl. 1, ISSN 0028-3878, page A277, XP009073089 [X] 1-32 * abstract *-
SEARCH- ENNS R ET AL, "Enact-2 safety, tolerability, and immunogenicity results of natalizumab in patients with Crohn's disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, & 69TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; ORLANDO, FL, USA; OCTOBER 29 -NOVEMBER 03, 2004, (200410), vol. 99, no. 10, Suppl. S, ISSN 0002-9270, page S269, XP009073091 [X] 1-32 * abstract *-
SEARCH[ ] - GASTROENTEROLOGY, DIGESTIVE DISEASE WEEK/105TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; NEW ORLEANS, LA, USA; MAY 16 20, 2004, (200404), vol. 126, no. 4, Suppl. 2, ISSN 0016-5085, page A463-
SEARCH- ROSKOS L K ET AL, "HUMAN ANTIGLOBULIN RESPONSES", MEASURING IMMUNITY, ELSEVIER,, NL, (200412), pages 172 - 186, XP008058931 [Y] 1-32 * paragraph bridging left- and right-hand columns on page 178; page 178, right-hand column, second paragraph; figure 13.3; page 181, right-hand column, second full paragraph *-
SEARCH- SANDS BRUCE E ET AL, "Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's disease", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200404), Database accession no. PREV200600085330, XP002401100 [X] 1-32 * abstract *-
SEARCH- BAERT F ET AL, "INFLUENCE OF IMMUNOGENICITY ON THE LONG-TERM EFFICACY OF INFLIXIMAB IN CROHN'S DISEASE", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20030213), vol. 348, no. 7, ISSN 1533-4406, pages 601 - 608, XP009037271 [Y] 1-32 * abstract; paragraph bridging pages 602 and 603 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents